Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has received an average rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $26.00.

A number of equities research analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Kalvista Pharmaceuticals in a research report on Friday, September 21st. They set an “overweight” rating and a $32.00 price target on the stock. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Wednesday, September 12th. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Roth Capital assumed coverage on Kalvista Pharmaceuticals in a research report on Tuesday, July 10th. They set a “buy” rating and a $20.00 price target on the stock.

NASDAQ KALV traded up $0.34 during trading hours on Friday, reaching $21.35. 4,837 shares of the company’s stock were exchanged, compared to its average volume of 130,914. The firm has a market cap of $363.34 million, a PE ratio of -13.76 and a beta of 3.07. Kalvista Pharmaceuticals has a one year low of $6.65 and a one year high of $22.46.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.14). The business had revenue of $3.72 million for the quarter, compared to the consensus estimate of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. research analysts anticipate that Kalvista Pharmaceuticals will post -1.78 earnings per share for the current year.

In other news, Director Albert Cha acquired 1,058,824 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 38.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Spark Investment Management LLC bought a new position in Kalvista Pharmaceuticals in the 2nd quarter valued at $108,000. BlackRock Inc. boosted its position in Kalvista Pharmaceuticals by 203.8% in the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 10,871 shares during the last quarter. DRW Securities LLC boosted its position in Kalvista Pharmaceuticals by 37.3% in the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock valued at $167,000 after buying an additional 5,600 shares during the last quarter. Stanley Laman Group Ltd. boosted its position in Kalvista Pharmaceuticals by 48.3% in the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after buying an additional 21,861 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its position in Kalvista Pharmaceuticals by 26.9% in the 1st quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock valued at $8,532,000 after buying an additional 191,000 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: How to Use the New Google Finance Tool

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.